Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Prescription, Nonprescription and Orphan Drugs

Prescription, Nonprescription and Orphan Drugs

Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...

Drug Classes and Categories

Drug Classes and Categories

Drugs can be classified according to their chemical composition or their intended therapeutic application. For instance, anti-infective agents that possess the ability to eliminate pathogens or suppress their growth and reproduction can be grouped based on the organisms they target or their chemical structure. Furthermore, drugs can be divided into prescription, nonprescription, or controlled substances. Prescription medications, such as antibiotics, require oversight from a licensed healthcare...

Drug Nomenclature

Drug Nomenclature

During the development of a new pharmaceutical, the manufacturer initially assigns a code name to the drug. Once approved, the drug receives a United States Adopted Name (USAN)—a generic, nonproprietary designation. Upon being listed in the United States Pharmacopeia, this nonproprietary name becomes the drug's official name. Additionally, the manufacturer assigns a proprietary name or trademark, which serves as the brand name under which the drug is marketed. It is worth noting that...

Drug Products: Biologics, Biosimilars and Interchangeables

Drug Products: Biologics, Biosimilars and Interchangeables

Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...

Modified-Release Drug Delivery Systems: Rate-Programmed II

Modified-Release Drug Delivery Systems: Rate-Programmed II

Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...

Modified-Release Drug Delivery Systems: Rate-Programmed I

Modified-Release Drug Delivery Systems: Rate-Programmed I

Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Bipartisan Drug-Patent Bills Ready for Senate Vote: Efforts Directed at Speeding Up Introduction of Generics.

P & T : a peer-reviewed journal for formulary management·2019

Same author

Democratic Presidential Candidates Lead Attack on Drug Prices: Health Insurance Expansions Tougher on Drugs than Dems' Bill in House.

P & T : a peer-reviewed journal for formulary management·2019

Same author

House Democrats Push Competing Drug Price Transparency Bills: May Provide Useful Data, But Not Downward Pressure on Prices.

P & T : a peer-reviewed journal for formulary management·2019

Same author

NIH Establishes Early Version of Personalized Medicine Platform.

P & T : a peer-reviewed journal for formulary management·2019

Same author

A Drug Pricing "Transparency" Bill With Strong Bipartisan Support But Would It Accomplish Much?

P & T : a peer-reviewed journal for formulary management·2019

Same author

HHS Proposes Steps Toward Health Data Interoperability CMS and ONC Proposals Would Implement Cures Act.

P & T : a peer-reviewed journal for formulary management·2019

Search research articles

Related Experiment Video

Updated: Feb 17, 2026

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis

Published on: December 17, 2021

Over-the-Counter Products In Line for User Fee Program.

P & T : a Peer-Reviewed Journal for Formulary Management

|December 14, 2017

Summary

Over-the-counter products are being considered for inclusion in a user fee program. This initiative aims to generate revenue for regulatory activities related to these widely available health products.

Area of Science:

Regulatory Science
Pharmaceutical Policy

Background:

Over-the-counter (OTC) products are readily accessible to consumers.
Existing regulatory frameworks may require additional funding for oversight.

Purpose of the Study:

To evaluate the feasibility and implications of including OTC products in a user fee program.
To explore potential revenue generation for regulatory agencies.

Main Methods:

Analysis of current OTC product market.
Review of existing user fee program structures.
Economic modeling of potential fee structures.

Main Results:

OTC products represent a significant market segment.
User fees could provide a sustainable funding stream.

More Related Videos

Use of the Operant Orofacial Pain Assessment Device OPAD to Measure Changes in Nociceptive Behavior

Use of the Operant Orofacial Pain Assessment Device OPAD to Measure Changes in Nociceptive Behavior

Published on: June 10, 2013

Author Spotlight: Optimizing EAS with Long Electrodes for Enhanced Cochlear Coverage and Hearing Preservation

Author Spotlight: Optimizing EAS with Long Electrodes for Enhanced Cochlear Coverage and Hearing Preservation

Published on: October 11, 2024

Related Experiment Videos

Last Updated: Feb 17, 2026

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis

Published on: December 17, 2021

Use of the Operant Orofacial Pain Assessment Device OPAD to Measure Changes in Nociceptive Behavior

Use of the Operant Orofacial Pain Assessment Device OPAD to Measure Changes in Nociceptive Behavior

Published on: June 10, 2013

Author Spotlight: Optimizing EAS with Long Electrodes for Enhanced Cochlear Coverage and Hearing Preservation

Author Spotlight: Optimizing EAS with Long Electrodes for Enhanced Cochlear Coverage and Hearing Preservation

Published on: October 11, 2024

Implementation requires careful consideration of market impact.

Conclusions:

Including OTC products in a user fee program is a viable option.
This approach could enhance regulatory oversight and compliance.
Further detailed analysis is recommended for policy development.